News & Events

Press Releases

June 13 2013

vasopharm Closes Series F Financing Round

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced the successful completion of a Series F financing round totalling €5 million (~ US$ 6.5 million). The round was led by existing investors HeidelbergCapital Private Equity and Entrepreneurs Fund (EF Investments S.à.r.l.). Bayern Kapital, another existing investor, also participated in the Series F round. The consortium was joined by new investors Hanseatic Asset Management LBG and Dr Andrew Clark, Chairman of the Board of vasopharm. The new consortium also acquired the shares of one of the founding investors seeking to exit.

Read on Download PDF
September 17 2012

vasopharm's Traumatic Brain Injury Drug Exceeds Expectations in Phase IIa Exploratory Clinical Trial

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIaNOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients. Traumatic Brain Injury is caused when an external force impacts the head. It is a condition with high unmet medical need and is the leading cause of death and disability among young adults in the developed world. TBI accounts for more potential years of life lost than cancer and cardiovascular disease combined and there are currently no drugs available to treat this condition.

Read on Download PDF
February 15 2011

New Chairman of Supervisory Board

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced the appointment of Dr Andrew Clark to its Supervisory Board. Dr Clark assumes the position as Chairman of the Board from Klaas de Boer who will remain as a member of vasopharm’s Board.

Read on Download PDF
June 8 2010

Continuation of NOSTRA trial with 2nd cohort

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced the receipt of the recommendation letter of an independent Drug Monitoring Committee to proceed with its clinical phase IIa NOSTRA trial (NO-Synthase inhibition in TRAumatic brain injury).

Read on Download PDF